Last reviewed · How we verify
NCT06951282
Impact of Selenium on Methotrexate Induced Spermatotoxicity; A Comparative Study
Phase 1, PHASE2 trial testing Selenium in Methotrexate Spermatotoxicity in 40 participants. Completed in 31 December 2024.
2 November 2024
Quick facts
| Lead sponsor | Ain Shams University |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 40 |
| Start date | 2 May 2024 |
| Primary completion | 2 November 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Selenium (SELENIUM) — full drug profile →
- Methotrexate — full drug profile →
Conditions studied
- Methotrexate Spermatotoxicity — all drugs for Methotrexate Spermatotoxicity →
Sponsor
Ain Shams University
Who can join
Adults 18 to 60, male only, with Methotrexate Spermatotoxicity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to assess the potential protective role of selenium on semen parameters and its effect on seminal glutathione peroxidase level in patients on MTX therapy
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06951282
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Selenium
Trials testing the same drug.
- NCT07334197 — Effect of Melatonin on Left Ventricular Reverse Remodeling and Inflammation in Peripartum Cardiomyopathy · NA · not yet recruiting
- NCT05672095 — Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer · Phase 1, PHASE2 · withdrawn
- NCT06413043 — Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy · NA · not yet recruiting
- NCT06362005 — The Efficacy of Selenium as an Alternative or Complementary Topical Treatment of Oral Lichen Planus · Phase 4 · completed
- NCT06117436 — Impact of Cilostazol Versus Cilostazol and Selenium Combination on the Healing of Diabetic Foot Ulcer Patients · Phase 2, PHASE3 · completed
Other Ain Shams University trials
Trials by the same sponsor.
- NCT07435493 — Fentanyl Versus Opioid Free Multimodal Analgesia for Perioperative Pain Control in Children With Mild to Moderate Obstru · NA · not yet recruiting
- NCT07482540 — Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery · NA · not yet recruiting
- NCT07531030 — Posterior Pericapsular Deep Gluteal Block Combined With Pericapsular Nerve Group and Lateral Femoral Cutaneous Nerve Blo · NA · not yet recruiting
- NCT06839027 — Arterial to Central co2gap in Relation to Outcome After Cardiopulmonary Bypass · not yet recruiting
- NCT07516535 — DISS vs FANS in Suction-Assisted RIRS for Medium-Sized Renal Stones · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06951282 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ain Shams University
- Last refreshed: 30 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06951282.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing